This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Novel CD20 monoclonal antibodies for lymphoma therapy
Journal of Hematology & Oncology Open Access 11 October 2012
-
Rituximab and new regimens for indolent lymphoma: a brief update from 2012 ASCO Annual Meeting
Cancer Cell International Open Access 23 August 2012
Access options
Subscribe to this journal
Receive 12 print issues and online access
We are sorry, but there is no personal subscription option available for your country.
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Coiffier B et al. (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346: 235–242
Feugier P et al. (2005) Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 23: 4117–4126
Pfreundschuh M et al. (2004) Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood 104: 626–633
Reyes F et al. (2005) ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med 352: 1197–1205
Habermann TM et al. (2006) Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 24: 3121–3127
Acknowledgements
The synopsis was written by Carol Lovegrove, Freelance Medical Writer.
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Coiffier, B. Rituximab and CHOP-like chemotherapy in good-prognosis diffuse large-B-cell lymphoma. Nat Rev Clin Oncol 3, 594–595 (2006). https://doi.org/10.1038/ncponc0638
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncponc0638
This article is cited by
-
Rituximab and new regimens for indolent lymphoma: a brief update from 2012 ASCO Annual Meeting
Cancer Cell International (2012)
-
Novel CD20 monoclonal antibodies for lymphoma therapy
Journal of Hematology & Oncology (2012)